메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Sisram Medical Reports First-Half 2025 Results: Injectables Su…

HONG KONG, Aug. 20, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; referred to collectively with its subsidiaries as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), and Injectables, alongside other complementary offerings, today announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period"). FINANCIAL HIGHLIGHTS Revenue was
- 김갑성 기자
- 2025-08-20 22:14
Zylox-Tonbridge Announces 2025 Interim Results: Strong Re…

HANGZHOU, China, Aug. 20, 2025 -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, hereinafter referred to as "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended June 30, 2025. The Company achieved robust revenue growth of 31.7% year-over-year (YoY) to RMB 482 million, while net profit surged by 76.0% to exceed RMB 121 million, representing a net profit margin of 25.1%. In the first half of 2025, Zylox-Tonbridge maintained solid performance in its core neurovascular and peripheral vascular intervention businesses
- 김갑성 기자
- 2025-08-20 21:41
IBM and NASA Release Groundbreaking Open-Source AI Mode…

[ 메디채널 김갑성 기자 ] The first heliophysics AI foundation model trained on high resolution solar observation data offers insights into the Sun's dynamic surface, helping plan for solar weather that can disrupt technology on Earth and in space Openly available on Hugging Face, the model was built to speed up scientific discovery and democratize AI for the global research and technology community Researchers also release the largest known curated heliophysics dataset to advance data driven space weather research YORKTOWN HEIGHTS, N.Y., Aug. 20, 2025 -- IBM (NYSE: IBM) and NAS
- 김갑성 기자
- 2025-08-20 21:00
Cell therapy is promising in treating psychiatric disorders, s…

SHANGHAI, Aug. 20, 2025 -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" in Cell Stem Cell, featured as a cover story. This study marks the first establishment of a technique to efficiently and directionally differentiate human pluripotent stem cells (hPSCs) into A10 subtype dopamine neurons. This breakthrough lays a critical scientific foundation for cell therapy of psychiatr
- 김갑성 기자
- 2025-08-20 20:49
Ping An Good Doctor (1833.HK) Reports Solid Interim Results with…

HONG KONG, Aug. 20, 2025 -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025, on August 19, 2025. Following its return to profitability in 2024, the Company maintained high growth and improved profitability during the reporting period, with core business development and continuous advancement in its medical AI capabilities. In terms of financial performance, the Company recorded revenue of RMB2.5 billion during the period, representing a year-on-year increase of
- 김갑성 기자
- 2025-08-20 19:19
First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1…

HONG KONG, Aug. 20, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso, in combination with chemotherapy for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. The COMPASSION-33 study represents the third Phase III trial for cadonilimab in gastric cancer. The study aims to improve the radical resectio
- 김갑성 기자
- 2025-08-20 16:11
DKSH Healthcare Establishes Industry Benchmark in Carbon…

DKSH Business Unit Healthcare has reached a significant milestone in building a more sustainable healthcare supply chain by successfully tracking carbon emissions across its value chain through a collaboration with UOB FinLab's GreenTech Accelerator and Smart Tradzt in Thailand. This achievement also marks the implementation of a reusable cold-chain packaging solution. The initiative underscores DKSH Healthcare's ongoing commitment to environmental responsibility and its proactive approach to advancing sustainable business practices. BANGKOK, Aug. 20, 2025 -- DKSH Business Unit
- 김갑성 기자
- 2025-08-20 12:00
Vital Materials Released Quantum Flux Photon Counting CT (P…

BEIJING, Aug. 20, 2025 -- From August 15-17, the 31st China International Medical Equipment Exhibition and Scientific Conference (China-Hospeq 2025) was held in Beijing. Vital Materials officially launched the VITA Genesis, China's fully proprietary Photon Counting CT (PCCT) scanner, marking the entry of global medical imaging technology into the "Quantum Flux" sensing era and empowering Chinese innovation in precision diagnostics and treatment. The Photon Counting Detectors (PCD), as the core technology of PCCT, differ significantly from traditional Energy Integratin
- 김갑성 기자
- 2025-08-20 10:45
XtalPi Signs MOU with Dong-A ST for Joint Research and Develo…

CAMBRIDGE, Mass., Aug. 20, 2025 -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using Xta
- 김갑성 기자
- 2025-08-20 08:00
ARC Therapies Advances Gut Microbiome Research with YB32…

[ 메디채널 김갑성 기자 ] Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy TOKYO, Aug. 20, 2025 -- ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research of YB328, a newly identified gut microbe, toward clinical application. Utilizing its proprietary intellectual property, the company has designated the YB328 strain as ARC0812 (RUX: "Lux") and will proceed with preclinical and human clinical trials to evaluate its administration methods and therapeutic e
- 김갑성 기자
- 2025-08-20 07:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분